Description

FOR RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION, VETERINARY USE, OR IN VIVO DIAGNOSTIC PURPOSES.

Product Overview: Ipamorelin

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) that acts as a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist. Recognized as one of the most selective growth hormone secretagogues available, Ipamorelin binds specifically to the growth hormone secretagogue receptor 1a (GHS-R1a) in the anterior pituitary gland to stimulate pulsatile Growth Hormone (GH) release. Unlike earlier secretagogues, Ipamorelin triggers robust GH secretion without stimulating cortisol, ACTH, prolactin, or appetite-inducing pathways, making it a gold-standard compound for endocrine research models.

Primary Purpose: Research settings utilize Ipamorelin primarily to study selective, pulsatile growth hormone secretion and downstream IGF-1 signaling—specifically by activating pituitary GHS-R1a receptors without triggering unwanted secondary hormone release (cortisol, prolactin) or appetite stimulation.

Primary Research Applications & Reasons for Study

Pulsatile Growth Hormone Release: Selectively binding to pituitary GHS-R1a receptors to induce natural, physiological growth hormone pulses.
GHRH Synergy Studies: Evaluating dual-pathway secretagogue combinations alongside GHRH analogs (such as CJC-1295) to measure amplified GH and IGF-1 secretion.
Bone Mineral Density & Osteogenesis: Investigating osteoblast proliferation, calcium retention, and cortical bone mineral density parameters in osteopenia/osteoporosis models.
Gastrointestinal Motility: Studying secondary prokinetic effects on bowel motility and postoperative ileus acceleration via peripheral ghrelin receptor pathways.

Expected Research Results & Timeline Metrics

Phase 1 / Minutes 15–60
Acute Growth Hormone Pulse: Rapid binding to GHS-R1a triggers an immediate, pronounced spike in serum growth hormone levels, peaking within ~30 minutes of administration.
Phase 2 / Weeks 1–3
Elevated IGF-1 & Nitrogen Retention: Sustained elevation of baseline circulating IGF-1 levels, improved nitrogen balance in muscle tissue assays, and initial shifts in lipolytic rate.
Phase 3 / Weeks 4–8+
Structural & Metabolic Adaptations: Statistically significant increases in bone mineral accretion, enhanced myofibrillar repair markers, and reduced adipocyte volume without desensitization of the pituitary axis.

Key Research Benefits

Exceptional Selectivity: Triggers robust GH release without elevating serum cortisol, ACTH, or prolactin concentrations.
No Appetite Stimulation: Bypasses NPY/AgRP hunger-stimulating pathways in the central nervous system despite binding ghrelin receptors.
High Combination Potential: Exhibits powerful, synergistic GH pulses when paired with GHRH analogs like CJC-1295.
Preserves Pituitary Feedback: Mimics natural physiological secretagogue pulses without shutting down endogenous pituitary response mechanisms.

Regulatory Compliance & Legal Research Disclaimer

THIS PRODUCT IS INTENDED SOLELY FOR IN VITRO LABORATORY RESEARCH AND EXPERIMENTAL PURPOSES. It is strictly prohibited for human consumption, clinical trials, therapeutic administration, cosmetic use, or veterinary application. This product is not an FDA-approved drug, medical food, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease, illness, or medical condition. Any handling, reconstitution, or experimentation involving this chemical compound must be conducted strictly by qualified, trained laboratory professionals utilizing appropriate containment and personal protective equipment in accordance with scientific biosafety standards. Buyers and users assume full liability for compliance with local, state, and federal laws regarding the handling and possession of research compounds.

Additional information

Size	5 mg